Skip to main content

An AI update: deep learning-based molecular de novo design in drug discovery

News


Abstract

Ola Engkvist is the Executive Director and Head of Molecular AI in Discovery Sciences within R&D at AstraZeneca (headquartered in Cambridge, UK). His team harnesses advanced computational technologies, including AI, with the aim of enhancing the discovery, design, optimization and synthesis of small molecules to be developed into innovative medicines. Their efforts significantly streamline the drug discovery
Key Data

  • Publication Date
    04 February 2025
  • Primary Author
    Ola Engkvist
  • Source
    BioTechniques
  • Language
    English
Click below to visit original source: